ABSTRACT
Polymyxin B and ethylenediaminetetraacetic acid are antimicrobials possessing antibiofilm activity. They act by displacement and chelation, respectively, of divalent cations in bacterial membranes and may therefore act synergistically when applied in combination. If so, this combination of agents may be useful for the treatment of diseases like cystic fibrosis (CF), in which biofilms are present on the respiratory epithelium. We used checkerboard assays to investigate the synergy between these agents using reference strains Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 6538 in planktonic form. We then determined the efficacy of each agent against biofilms of both species grown on 96-pin lids and proceeded to combination testing against the P. aeruginosa reference strain and 10 clinical isolates from patients with CF. Synergism was observed for planktonic forms of both species and for biofilms of P. aeruginosa. The susceptibility of biofilms of P. aeruginosa clinical isolates to these agents was variable compared to the laboratory reference strain. This combination of agents may be useful in the management of biofilm-associated conditions, particularly those amenable to topical therapies. These results provide a basis upon which the antimicrobial and antibiofilm efficacy of preparations containing these agents may be enhanced.IMPORTANCEBacteria living in biofilms produce a protective matrix which makes them difficult to kill. Patients with severe respiratory disease often have biofilms. Polymyxin B is an antibiotic commonly used in topical medications, such as eye drops and nasal sprays. Ethylenediaminetetraacetic acid (EDTA) is used widely as a preservative in medication but also has antimicrobial properties. It has been hypothesized that Polymyxin B and EDTA could have a synergistic relationship: when used in combination their antimicrobial effect is enhanced. Here, we evaluated the levels at which Polymyxin B and EDTA work together to kill common pathogens Pseudomonas aeruginosa and Staphylococcus aureus. We found that Polymyxin B and EDTA were synergistic. This synergy may be useful in the management of planktonic infection with P. aeruginosa and S. aureus, or biofilm infection with P. aeruginosa. This synergy may be beneficial in the treatment of respiratory biofilms, in which P. aeruginosa biofilms are common.
Subject(s)
Anti-Infective Agents , Cystic Fibrosis , Pseudomonas Infections , Staphylococcal Infections , Humans , Polymyxin B/therapeutic use , Edetic Acid , Pseudomonas aeruginosa , Staphylococcus aureus , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Biofilms , Cystic Fibrosis/microbiology , Microbial Sensitivity TestsABSTRACT
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have changed the clinical landscape of cystic fibrosis (CF) by improving clinically significant outcome measures and quality of life of people with CF (pwCF). There are now long-term data showing improved 5-year survival with the use of ivacaftor, and the field continues to evolve at a rapid pace with the continued development of highly effective CFTR modulators. While the randomized controlled trials of CFTR modulators excluded patients with severe lung disease (forced expiratory volume in 1 second <40% predicted), observational data based on case reports and registry data show similar benefits in those with advanced lung disease. This has altered clinical practice particularly as it pertains to the role of lung transplantation in CF. This article describes the impact of highly effective modulator therapy (HEMT) on the natural history of CF and the influence on the timing of referral and consideration of listing for lung transplantation. CF clinicians play a pivotal role to ensure that the impetus of the CF foundation consensus guidelines to facilitate timely referral for lung transplantation is not lost among the excitement of anticipated sustained benefit from HEMT. While the widespread availability of elexacaftor/tezacaftor/ivacaftor over the past 2 years has been associated with a sharp drop in the number of people referred for consideration for lung transplantation and the number of people wait-listed for lung transplantation, it is difficult to accurately determine the true impact due to the confounding effect of the coronavirus disease 2019 pandemic. It is expected that lung transplantation will remain an important treatment for a smaller number of pwCF. Lung transplantation offers survival benefits in CF, and there remains an imperative to ensure timely consideration of lung transplantation in patients with advanced disease to further reduce the number of pwCF dying without consideration of lung transplant.
Subject(s)
COVID-19 , Cystic Fibrosis , Lung Transplantation , Humans , Cystic Fibrosis/drug therapy , Cystic Fibrosis/surgery , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Quality of Life , MutationABSTRACT
Surgical repair of right-sided bronchial dehiscence post lung transplant is challenging. We report a hybrid reconstruction of the bronchus using an aortic homograft patch with stenting as a novel technique of management of ischemic airway injury following lung transplantation.
Subject(s)
Allografts , Aorta/transplantation , Bronchi/surgery , Bronchomalacia/surgery , Lung Transplantation/adverse effects , Necrosis/surgery , Plastic Surgery Procedures/methods , Postoperative Complications/surgery , Stents , Bronchi/pathology , Constriction, Pathologic/surgery , Humans , Male , Middle AgedABSTRACT
The use of aortic homograft in infective pathology is well described. Its use in the repair of post-transplant airway complications has been seldom reported. Herein, we report our experience with the successful use of aortic homograft in the management of post-transplant large airway complications in two patients.
Subject(s)
Aorta/transplantation , Bronchi/surgery , Lung Diseases/surgery , Lung Transplantation/adverse effects , Surgical Wound Dehiscence/surgery , Adult , Bronchi/pathology , Humans , Lung Diseases/etiology , Lung Diseases/pathology , Male , Middle Aged , Reoperation , Salvage Therapy , Surgical Wound Dehiscence/diagnosis , Surgical Wound Dehiscence/etiology , Transplantation, HomologousABSTRACT
We describe the intraoperative surgical management of tracheal bronchus encountered in a lung transplant recipient.
Subject(s)
Bronchi/abnormalities , Bronchi/surgery , Bronchopulmonary Dysplasia/surgery , Lung Transplantation , Trachea/abnormalities , Trachea/surgery , Adult , Anastomosis, Surgical/methods , Bronchi/diagnostic imaging , Bronchopulmonary Dysplasia/diagnostic imaging , Bronchoscopy , Humans , Male , Plastic Surgery Procedures/methods , Tomography, X-Ray Computed , Trachea/diagnostic imagingABSTRACT
BACKGROUND: Important risk factors for long-term survival of lung transplant (LT) recipients are infection, acute graft rejection (AR) and chronic lung allograft dysfunction (CLAD). Socioeconomic deprivation (SED) is associated with increased graft failure rate after heart and kidney transplantation, but has not been investigated in LT recipients. The aim of this study was to evaluate an association between LT recipients' SED status and development of AR, CLAD, and long-term survival. METHODS: This was a retrospective cohort study. Over a 23 y period, 233 patients were identified from the Auckland City Hospital Lung Transplant Registry, Auckland, New Zealand. All patients were divided into two groups according to the 2013 New Zealand Deprivation Index Score. RESULTS: The incidence of AR in the higher SED group was 34.0/100 person-y (95% confidence interval [CI]: 24.7-46.7/100 person-y) and in the lower SED group 40.2/100 person-y (95% CI: 33.5-48.3/100 person-y) (P = 0.373). The incidence of CLAD in the higher SED group was 10.7/100 person-y (95% CI: 6.2-18.4/100 person-y) and 9.3 (6.9-12.5/100 person-y) in the lower SED group (P = 0.645). Mortality in the higher SED group was 12.9/100 person-y (95% CI: 9.2-17.9/100 person-y) and 12.4/100 person-y (95% CI: 10.0-15.3/100 person-y) in the lower SED group (P = 0.834). CONCLUSIONS: SED status of LT recipients in New Zealand has no negative effect on development of AR, CLAD, and patients' survival.
Subject(s)
Graft Rejection/epidemiology , Lung Transplantation/adverse effects , Respiratory Insufficiency/surgery , Socioeconomic Factors , Transplant Recipients/statistics & numerical data , Adolescent , Adult , Female , Graft Survival , Humans , Incidence , Male , Middle Aged , New Zealand/epidemiology , Registries/statistics & numerical data , Respiratory Insufficiency/mortality , Retrospective Studies , Risk Factors , Survival Analysis , Young AdultABSTRACT
BACKGROUND: Several cases of Burkholderia pseudomallei infection in CF have been previously reported. We aimed to identify all cases globally, risk factors for acquisition, clinical consequences, and optimal treatment strategies. METHODS: We performed a literature search to identify all published cases of B. pseudomallei infection in CF. In addition we hand-searched respiratory journals, and contacted experts in infectious diseases and CF around the world. Supervising clinicians for identified cases were contacted and contemporaneous clinical data was requested. RESULTS: 25 culture-confirmed cases were identified. The median age at acquisition was 21 years, mean FEV1 % predicted was 60 %, and mean BMI was 19.5 kg/m(2). The location of acquisition was northern Australia or south-east Asia for most. 19 patients (76 %) developed chronic infection, which was usually associated with clinical decline. Successful eradication strategies included a minimum of two weeks of intravenous ceftazidime, followed by a consolidation phase with trimethoprim/sulfamethoxazole, and this resulted in a higher chance of success when instituted early. Three cases of lung transplantation have been recorded in the setting of chronic B. pseudomallei infection. CONCLUSION: Chronic carriage of B. pseudomallei in patients with CF appears common after infection, in contrast to the non-CF population. This is often associated with an accelerated clinical decline. Lung transplantation has been performed in select cases of chronic B. pseudomallei infection.
Subject(s)
Burkholderia pseudomallei , Cystic Fibrosis/epidemiology , Melioidosis/epidemiology , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Australasia/epidemiology , Ceftazidime/therapeutic use , Child , Cystic Fibrosis/physiopathology , Europe/epidemiology , Female , Forced Expiratory Volume , Humans , Male , Melioidosis/drug therapy , North America/epidemiology , Retrospective Studies , Young AdultABSTRACT
Broncho-pleural fistulae (BPF) are recognised as a rare complication following pneumonectomy. We describe a patient, who after failing conservative treatment, underwent closure of a persistent fistula with an atrial septal defect (ASD) occluder. Additionally we review the literature regarding management of BPF and the emerging role of cardiac defect closure devices as a possible treatment option.
Subject(s)
Bronchi , Bronchial Fistula , Heart Septal Defects, Atrial , Pleura , Pneumonectomy/adverse effects , Postoperative Complications , Aged, 80 and over , Bronchi/pathology , Bronchi/surgery , Bronchial Fistula/etiology , Bronchial Fistula/pathology , Bronchial Fistula/surgery , Heart Septal Defects, Atrial/pathology , Heart Septal Defects, Atrial/surgery , Humans , Male , Postoperative Complications/pathology , Postoperative Complications/surgeryABSTRACT
In this study, the suitability of two repetitive-element-based PCR (rep-PCR) assays, enterobacterial repetitive intergenic consensus (ERIC)-PCR and BOX-PCR, to rapidly characterize Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis (CF) was examined. ERIC-PCR utilizes paired sequence-specific primers and BOX-PCR a single primer that target highly conserved repetitive elements in the P. aeruginosa genome. Using these rep-PCR assays, 163 P. aeruginosa isolates cultured from sputa collected from 50 patients attending an adult CF clinic and 50 children attending a paediatric CF clinic were typed. The results of the rep-PCR assays were compared to the results of PFGE. All three assays revealed the presence of six major clonal groups shared by multiple patients attending either of the CF clinics, with the dominant clonal group infecting 38 % of all patients. This dominant clonal group was not related to the dominant clonal group detected in Sydney or Melbourne (pulsotype 1), nor was it related to the dominant groups detected in the UK. In all, PFGE and rep-PCR identified 58 distinct clonal groups, with only three of these shared between the two clinics. The results of this study showed that both ERIC-PCR and BOX-PCR are rapid, highly discriminatory and reproducible assays that proved to be powerful surveillance screening tools for the typing of clinical P. aeruginosa isolates recovered from patients with CF.